Cytokine release syndrome (CAR-T / immunotherapy)
Systemic inflammatory response · Shock / Sepsis
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Immune-cell therapies (CAR-T, bispecific antibodies) can trigger a systemic cytokine storm with fever, hypotension and hypoxia, sometimes with neurotoxicity (ICANS). Supportive care plus tocilizumab and steroids by grade are the mainstays.
Assessment
Investigations
- Identify recent CAR-T/immunotherapy
- Septic screen (CRS mimics sepsis)
- Grade severity (fever, vasopressor/oxygen need)
- Assess for neurotoxicity (ICANS)
Management
- Resuscitate and cover for sepsis until excluded
- Tocilizumab for significant CRS
- Corticosteroids for higher grades or neurotoxicity
- Organ support (vasopressors, oxygen) as needed
- Haematology/oncology and ICU involvement
Drugs & doses
Tocilizumab
Corticosteroids
Vasopressors / fluids
Disposition
ICU; haematology.
Fever and shock days after CAR-T is cytokine release syndrome - treat sepsis in parallel, and reach for tocilizumab.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.